Incanthera upbeat on 'Sol' skin sensitisation study
Specialist oncology company Incanthera reported positive data from a skin sensitisation study of its skin cancer technology ‘Sol’ on Monday.
The firm described Sol as a proprietary topical formulation designed to deliver an active known to prevent the formation of solar, or actinic, keratosis and skin cancer into the skin.
It said the study, conducted by XCellR8, demonstrated that the Sol formulation was found to be ‘non-irritant’ using ex-vivo human skin.
Formerly, studies carried out in collaboration between XCellR8 and contract research organisation Cutest demonstrated a “very good” correlation between results using the methodology of the study, and those obtained in clinical mildness studies.
Sol's non-irritancy was found to be comparable to baby sun protection products tested previously, with Sol scoring better than those products which were defined as ‘very mild’.
The company said it was “delighted” with the results, explaining that the “comfort and safety” of the reaction of human skin to the topical application of Sol was a further valuable marker of the asset and technology.
It said the results added to the data announced on 22 September, showing the “exemplary” penetration capabilities of Sol into the skin where it could deliver the required bioequivalent level shown to be clinically effective.
“This additional positive data on Sol, greatly enhances the product's overall profile and supports our ongoing negotiations with potential commercial partners,” said chairman Tim McCarthy.